No support shown for the use of pycnogenol for chronic disorders

February 15, 2012 By Milly Dawson

The manufacturer of a dietary supplement made from French pine bark, Pycnogenol, markets it widely for the prevention or treatment of many chronic disorders, ranging from asthma to erectile dysfunction, but a recent systematic review found no sound basis for the claims.

“We found that no solid evidence exists to support health claims that are being made for the antioxidant supplement Pycnogenol,” said senior author Jimmy Volmink, M.D., Ph.D., Dean of the Faculty of Health Sciences at Stellenbosch University in South Africa and director of the SA Cochrane Centre, Medical Research Council of South Africa. “Only 15 randomized controlled trials…have evaluated the effects of Pycnogenol.” The manufacturer sponsored 11 of them.

Pycnogenol is derived from the bark of pine trees that grow only in southern France. It contains the antioxidant proanthocyanidin, which is present in fruits, red wine and chocolate.

Dietary supplements represent a multibillion industry, notes Volmink. “Steps are currently being taken in several countries to improve the regulation of the industry, in terms of quality, safety and the validity of health claims.” Meanwhile, consumers must interpret claims cautiously, he said.

The fifteen trials - performed in the USA, Europe, China and Iran - involved 791 participants. The disorders studied included , attention deficit hyperactivity disorder, chronic venous insufficiency, diabetes, erectile dysfunction, hypertension and osteoarthritis. Two trials were done with children; the rest with adults.

The new review's authors could draw no solid conclusions regarding benefits that many studies purported to find. The 15 trials exhibited poor quality, with small sample sizes (11 to 156 participants) and often inadequate blinding. Key results were sometimes missing for relevant outcomes and some trials provided results only for the treatment group taking Pycnogenol®, but not for controls.

Roberta W. Scherer, Ph.D., an associate scientist at the Johns Hopkins Bloomberg School of Public Health said, “A majority of the studies were funded by the manufacturer, leading to increased risk of bias.” She noted that because the trials had small samples, it is difficult to have confidence in the findings. The trials also examined diverse outcomes, making combining the results difficult or impossible. “Also, safety is hard to assess with small trials,” she said. “It’s not really shown” in small, short-term trials like those done on Pycnogenol.

Both scientists called for bigger, better studies of Pycnogenol before consumers can trust in its efficacy and safety.

Explore further: For a less biased study, try randomization

More information: Schoonees A., Visser J., Musekiwa A., Volmink J. (2012). Pycnogenol® for the treatment of chronic disorders. The Cochrane Library, Issue 2.

Related Stories

For a less biased study, try randomization

April 13, 2011
A new review of existing research confirms that the so-called “gold standard” of medical research — the randomized controlled study — provides a safeguard against bias.

Reminder packaging helps patients take medications as directed

September 14, 2011
People with chronic illnesses are more likely to take long-term medications according to doctors’ instructions if the packaging includes a reminder system, according to a new review of evidence.

Recommended for you

Vaccinating against psoriasis, allergies and Alzheimer's a possibility, research shows

October 23, 2017
Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against ...

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.